# Allogene Therapeutics, Inc.: financial statements, quarterly

ALLO · Nasdaq · CIK 1737287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/allo.md) · [Financials](/companies/allo/financials.md) · [Filings](/companies/allo/filings.md) · [Insiders](/companies/allo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/allo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001737287-24-000073.md) | [0.0 d](/filings/0001737287-25-000036.md) | [0.0](/filings/0001737287-25-000064.md) | [0.0](/filings/0001737287-25-000088.md) | [0.0](/filings/0001628280-25-050230.md) | [0.0 d](/filings/0001628280-26-017242.md) | [0.0](/filings/0001737287-25-000064.md) | [0.0](/filings/0001628280-26-056213.md) | [0.0](/filings/0001628280-25-050230.md) | [0.0 d](/filings/0001628280-26-017242.md) | not reported | [4.6](/filings/0001628280-26-056213.md) |
| Research and development | $m | [46.0](/filings/0001737287-24-000073.md) | [54.7 d](/filings/0001737287-25-000036.md) | [52.3](/filings/0001737287-25-000064.md) | [50.4](/filings/0001737287-25-000088.md) | [44.7](/filings/0001628280-25-050230.md) | [45.0 d](/filings/0001628280-26-017242.md) | [50.2](/filings/0001628280-26-034585.md) | [40.2](/filings/0001628280-26-056213.md) | [31.2](/filings/0001628280-25-050230.md) | [28.6 d](/filings/0001628280-26-017242.md) | [32.0](/filings/0001628280-26-034585.md) | [30.7](/filings/0001628280-26-056213.md) |
| Operating income | $m | [(63.0)](/filings/0001737287-24-000073.md) | [(85.1) d](/filings/0001737287-25-000036.md) | [(69.5)](/filings/0001737287-25-000064.md) | [(71.4)](/filings/0001737287-25-000088.md) | [(71.8)](/filings/0001628280-25-050230.md) | [(60.5) d](/filings/0001628280-26-017242.md) | [(65.2)](/filings/0001628280-26-034585.md) | [(56.8)](/filings/0001628280-26-056213.md) | [(44.9)](/filings/0001628280-25-050230.md) | [(42.4) d](/filings/0001628280-26-017242.md) | [(46.1)](/filings/0001628280-26-034585.md) | [(46.9)](/filings/0001628280-26-056213.md) |
| Interest expense | $m | [0.0](/filings/0001737287-24-000073.md) | [0.0 d](/filings/0001737287-25-000036.md) | [0.0](/filings/0001737287-25-000064.md) | [0.0](/filings/0001737287-25-000088.md) | [0.1](/filings/0001628280-25-050230.md) | [0.1 d](/filings/0001628280-26-017242.md) | [0.2](/filings/0001628280-26-034585.md) | [0.3](/filings/0001628280-26-056213.md) | [0.3](/filings/0001628280-25-050230.md) | [0.3 d](/filings/0001628280-26-017242.md) | [0.3](/filings/0001628280-26-034585.md) | [0.3](/filings/0001628280-26-056213.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(62.3)](/filings/0001737287-24-000073.md) | [(85.8) d](/filings/0001737287-25-000036.md) | [(65.0)](/filings/0001628280-25-050230.md) | [(66.4)](/filings/0001628280-25-050230.md) | [(66.3)](/filings/0001628280-25-050230.md) | [(59.9) d](/filings/0001628280-26-017242.md) | [(59.7)](/filings/0001628280-26-056213.md) | [(50.9)](/filings/0001628280-26-056213.md) | [(41.4)](/filings/0001628280-25-050230.md) | [(38.8) d](/filings/0001628280-26-017242.md) | [(42.6)](/filings/0001628280-26-056213.md) | [(42.7)](/filings/0001628280-26-056213.md) |
| Diluted EPS | $ per share | [(0.37)](/filings/0001737287-24-000073.md) | not reported | [(0.38)](/filings/0001737287-25-000064.md) | [(0.35)](/filings/0001737287-25-000088.md) | [(0.32)](/filings/0001628280-25-050230.md) | not reported | [(0.28)](/filings/0001628280-26-034585.md) | [(0.23)](/filings/0001628280-26-056213.md) | [(0.19)](/filings/0001628280-25-050230.md) | not reported | [(0.18)](/filings/0001628280-26-034585.md) | [(0.13)](/filings/0001628280-26-056213.md) |
| Basic EPS | $ per share | [(0.37)](/filings/0001737287-24-000073.md) | not reported | [(0.38)](/filings/0001737287-25-000064.md) | [(0.35)](/filings/0001737287-25-000088.md) | [(0.32)](/filings/0001628280-25-050230.md) | not reported | [(0.28)](/filings/0001628280-26-034585.md) | [(0.23)](/filings/0001628280-26-056213.md) | [(0.19)](/filings/0001628280-25-050230.md) | not reported | [(0.18)](/filings/0001628280-26-034585.md) | [(0.13)](/filings/0001628280-26-056213.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [69.2](/filings/0001737287-24-000021.md) | [83.2](/filings/0001737287-25-000036.md) | [51.0](/filings/0001737287-24-000041.md) | [171](/filings/0001737287-24-000056.md) | [51.2](/filings/0001737287-24-000073.md) | [75.2](/filings/0001628280-26-017242.md) | [42.5](/filings/0001737287-25-000064.md) | [52.3](/filings/0001737287-25-000088.md) | [37.8](/filings/0001628280-25-050230.md) | [51.7](/filings/0001628280-26-056213.md) | [30.3](/filings/0001628280-26-034585.md) | [38.6](/filings/0001628280-26-056213.md) |
| Current assets | $m | [473](/filings/0001737287-24-000021.md) | [459](/filings/0001737287-25-000036.md) | [395](/filings/0001737287-24-000041.md) | [457](/filings/0001737287-24-000056.md) | [304](/filings/0001737287-24-000073.md) | [303](/filings/0001628280-26-017242.md) | [292](/filings/0001737287-25-000064.md) | [283](/filings/0001737287-25-000088.md) | [261](/filings/0001628280-25-050230.md) | [258](/filings/0001628280-26-056213.md) | [273](/filings/0001628280-26-034585.md) | [340](/filings/0001628280-26-056213.md) |
| Total assets | $m | [713](/filings/0001737287-24-000021.md) | [643](/filings/0001737287-25-000036.md) | [586](/filings/0001737287-24-000041.md) | [647](/filings/0001737287-24-000056.md) | [589](/filings/0001737287-24-000073.md) | [549](/filings/0001628280-26-017242.md) | [508](/filings/0001737287-25-000064.md) | [471](/filings/0001737287-25-000088.md) | [440](/filings/0001628280-25-050230.md) | [416](/filings/0001628280-26-056213.md) | [396](/filings/0001628280-26-034585.md) | [550](/filings/0001628280-26-056213.md) |
| Current liabilities | $m | [37.5](/filings/0001737287-24-000021.md) | [37.1](/filings/0001737287-25-000036.md) | [30.9](/filings/0001737287-24-000041.md) | [37.3](/filings/0001737287-24-000056.md) | [32.6](/filings/0001737287-24-000073.md) | [35.5](/filings/0001628280-26-017242.md) | [30.0](/filings/0001737287-25-000064.md) | [31.7](/filings/0001737287-25-000088.md) | [31.8](/filings/0001628280-25-050230.md) | [32.5](/filings/0001628280-26-056213.md) | [28.3](/filings/0001628280-26-034585.md) | [31.7](/filings/0001628280-26-056213.md) |
| Total liabilities | $m | [133](/filings/0001737287-24-000021.md) | [131](/filings/0001737287-25-000036.md) | [125](/filings/0001737287-24-000041.md) | [132](/filings/0001737287-24-000056.md) | [125](/filings/0001737287-24-000073.md) | [127](/filings/0001628280-26-017242.md) | [123](/filings/0001737287-25-000064.md) | [126](/filings/0001737287-25-000088.md) | [124](/filings/0001628280-25-050230.md) | [123](/filings/0001628280-26-056213.md) | [117](/filings/0001628280-26-034585.md) | [114](/filings/0001628280-26-056213.md) |
| Shareholders' equity | $m | [581](/filings/0001737287-24-000073.md) | [512](/filings/0001628280-26-017242.md) | [461](/filings/0001628280-25-050230.md) | [515](/filings/0001628280-25-050230.md) | [464](/filings/0001628280-25-050230.md) | [422](/filings/0001628280-26-056213.md) | [385](/filings/0001628280-26-056213.md) | [345](/filings/0001628280-26-056213.md) | [315](/filings/0001628280-25-050230.md) | [293](/filings/0001628280-26-056213.md) | [279](/filings/0001628280-26-056213.md) | [436](/filings/0001628280-26-056213.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(55.5) d](/filings/0001737287-24-000073.md) | [(53.7) d](/filings/0001737287-25-000036.md) | [(55.9)](/filings/0001737287-25-000064.md) | [(63.6) d](/filings/0001737287-25-000088.md) | [(44.1) d](/filings/0001628280-25-050230.md) | [(36.7) d](/filings/0001628280-26-017242.md) | [(52.9)](/filings/0001628280-26-034585.md) | [(39.0) d](/filings/0001628280-26-056213.md) | [(29.7) d](/filings/0001628280-25-050230.md) | [(27.6) d](/filings/0001628280-26-017242.md) | [(12.9)](/filings/0001628280-26-034585.md) | [(32.0) d](/filings/0001628280-26-056213.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001737287-24-000073.md) | [0.2 d](/filings/0001737287-25-000036.md) | [0.0](/filings/0001737287-25-000064.md) | [0.0 d](/filings/0001737287-25-000088.md) | [0.4 d](/filings/0001628280-25-050230.md) | [0.3 d](/filings/0001628280-26-017242.md) | [0.1](/filings/0001628280-26-034585.md) | [0.0 d](/filings/0001628280-26-056213.md) | [0.2 d](/filings/0001628280-25-050230.md) | [0.0 d](/filings/0001628280-26-017242.md) | [0.0](/filings/0001628280-26-034585.md) | [0.2 d](/filings/0001628280-26-056213.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [144](/filings/0001737287-24-000021.md) | [145](/filings/0001737287-24-000041.md) | [147](/filings/0001737287-24-000056.md) | [168](/filings/0001737287-24-000073.md) | [169](/filings/0001737287-25-000064.md) | [190](/filings/0001737287-25-000088.md) | [209](/filings/0001628280-25-050230.md) | [215](/filings/0001628280-26-034585.md) | [219](/filings/0001628280-26-056213.md) | [222](/filings/0001628280-25-050230.md) | [240](/filings/0001628280-26-034585.md) | [329](/filings/0001628280-26-056213.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 345,490,881 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001628280-26-056213.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.